| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Tecarfarin targets vitamin K epoxide reductase (VKOR), specifically the VKORC1 subunit. It acts as a non-competitive antagonist with an IC50 of 0.67 μM against VKORC1. By inhibiting VKOR, tecarfarin blocks the recycling of vitamin K epoxide to its active reduced form, thereby impairing the post-translational modification (gamma-carboxylation) of vitamin K-dependent clotting factors II, VII, IX, and X. This reduces their levels and activity, producing an antithrombotic effect.
|
|---|---|
| ln Vitro |
In vitro, tecarfarin is a potent VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. It acts as a non-competitive antagonist. The compound also functions as a cannabinoid-1 receptor inverse agonist. Its antithrombotic activity is mediated through impairment of vitamin K-dependent clotting factor activation.
|
| ln Vivo |
In vivo, tecarfarin is orally active and produces antithrombotic effects by reducing the levels and activity of vitamin K-dependent clotting factors II, VII, IX, and X. It prolongs prothrombin time. The compound also attenuates abdominal pain and increases intestinal transit in mice. Unlike warfarin, tecarfarin is not affected by CYP2C9 and CYP3A4 inhibition, providing a more predictable anticoagulant response.
|
| Enzyme Assay |
In vitro enzyme assays for tecarfarin measure its inhibition of VKOR activity. Microsomal preparations containing VKOR are incubated with vitamin K epoxide and varying concentrations of the compound. The conversion of vitamin K epoxide to vitamin K is quantified by HPLC or other analytical methods. The IC50 of 0.67 μM against VKORC1 is determined from dose-response curves. Binding assays for the cannabinoid-1 receptor can also be performed.
|
| Cell Assay |
In vitro cell-based assays for tecarfarin assess its effects on vitamin K-dependent clotting factor production. Cells such as hepatocytes are treated with serial dilutions of the compound, and the production of functional clotting factors II, VII, IX, and X is measured by coagulation assays or ELISA. The compound's effects on cell viability and proliferation are assessed in parallel.
|
| Animal Protocol |
In vivo animal models for tecarfarin include mouse and rat models of thrombosis. The compound is administered orally, and its antithrombotic efficacy is evaluated by measuring thrombus formation in arterial or venous thrombosis models. Prothrombin time is measured as a pharmacodynamic marker of VKOR inhibition. The compound's effects on abdominal pain and intestinal transit are assessed in mouse models.
|
| ADME/Pharmacokinetics |
Tecarfarin has a molecular formula of C21H14F6O5 and a molecular weight of 460.32. It is orally bioavailable and is administered orally in preclinical and clinical studies. Unlike warfarin, tecarfarin is metabolized via non-CYP pathways and is not affected by CYP2C9 and CYP3A4 inhibition. This provides a more predictable pharmacokinetic profile and reduces the risk of drug interactions.
|
| Toxicity/Toxicokinetics |
The toxicity profile of tecarfarin is similar to that of other vitamin K antagonists. The primary safety concern is bleeding risk due to reduced clotting factor activity. The compound is contraindicated in patients with bleeding disorders or those at high risk of hemorrhage. Drug interactions are minimized due to its non-CYP metabolic pathway. The compound's safety margin is determined from preclinical toxicology studies.
|
| References |
|
| Additional Infomation |
Ticarfaline has been used in trials investigating the prevention of thrombosis and thromboembolism.
Tecarfarin (ATI-5923) is a Phase-3-ready vitamin K antagonist with a non-cytochrome P450 metabolic profile. It is also known as ATI-5923. Unlike warfarin, tecarfarin is not affected by CYP2C9 and CYP3A4 inhibition, offering a more predictable anticoagulant response. The compound also functions as a cannabinoid-1 receptor inverse agonist. It is used for research purposes and is not approved for clinical use. |
| Molecular Formula |
C21H14F6O5
|
|---|---|
| Molecular Weight |
460.32326
|
| Exact Mass |
460.075
|
| CAS # |
867257-26-9
|
| Related CAS # |
Tecarfarin sodium;1004551-83-0
|
| PubChem CID |
54718618
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.129
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=CC(CC2=C(O)C3C(=CC=CC=3)OC2=O)=CC=1)OC(C(F)(F)F)(C(F)(F)F)C
|
| InChi Key |
QFLNTQDOVCLQKW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
|
| Chemical Name |
1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-((4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzoate
|
| Synonyms |
ATI-5923 ATI 5923 ATI5923
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~543.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1724 mL | 10.8620 mL | 21.7240 mL | |
| 5 mM | 0.4345 mL | 2.1724 mL | 4.3448 mL | |
| 10 mM | 0.2172 mL | 1.0862 mL | 2.1724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA